Abstract 4441
Background
Cryo is an effective intervention for palliation and local control for small primary and metastatic tumours in mRCC. Pre-clinical murine tumour modeling found cryo recruits effector immune cells and synergizes with anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) to inhibit tumour rechallenge as compared to either therapy (tx) alone, leading to a prospective pilot study evaluating safety/tolerability.
Methods
NCT02626130 randomized pts to treme (CTLA-4) 10mg/kg every 4 weeks alone (arm A) or after cryo (arm B) for two doses followed by surgery (sx) or biopsy (bx) followed by maintenance treme. Best confirmed responses (ORR) were defined using RECIST v1.1, toxicity (tox) tabulated using CTCAE v4 with ≥ grade 3 adverse events (AE) possibly related reported, and time on study was defined as event free survival (EFS). Immune monitoring data (IMD): tissue based IHC, CyTOF, and RNA Nanostring.
Results
30 pts accrued, 29 pts received tx on study. More patients in Arm B had intermediate and poor risk disease as per IMDC criteria and had received >1 line of treatment as compared to Arm A leading to an imbalance between arms. Toxicity on study was similar between arms with six patients on each arm requiring treatment discontinuation due to AEs. IMD found clear cell histology (CC) had an inflamed tumor microenvironment (TME) with increased immune infiltration (IC) post treme in both arms compared to non-clear cell (NCC). CyTOF analysis identified an activated CD4+ T cell cluster expressing ICOS in the TME of CC pts compared to NCC.
Conclusions
Cryo+treme was tolerated similar to treme alone. IMD found a differential TME response to treme in CC vs NCC pts and in EFS >3 mo vs EFS <3 mo. Longer follow up is needed to determine impact of cryo in clinical efficacy endpoints.Table:
963P
Arm A n = 14 | Arm B n = 15 | |
---|---|---|
Histology Clear cell (CC) Non-clear cell (NCC) | 9 5 | 9 6 |
IMDC Good (CC/NCC) Intermediate Poor | 4 (4/0) 9 (5/4) 1 (0/1) | 0 11 (6/5) 4 (3/1) |
Prior nephrectomy | 7 (50%) | 5 (33%) |
Prior treatment 0 1 >1 | 10 2 2 | 10 0 5 |
Tissue collected | 6 sx, 4 bx, 4 no tissue | 5 sx, 4 bx, 6 NT |
ORR All (CC/NCC) PR SD PD Not measurable | 0 9 (7/2) 3 (2/1) 2 (0/2) | 1 (1/0) 4 (3/1) 5 (1/4) 5 (4/1) |
EFS mo (Arm A v Arm B) | 4.9 vs 3.2 (HR 0.73, 95%CI 0.35-1.58) | |
EFS mo (CC v NCC) | 3.3 vs 2.9 (HR 1.16, HR 95%CI 0.54-2.51) | |
EFS > 6 mo, #pts, (range) | Arm A: 4 (7.6-29.9), Arm B: 3 (6.3-30.3) | |
EFS> 6 mo (range) CC v NCC | CC: 4 (11.7-30.3), NCC 3 (6.3-7.8) |
Clinical trial identification
NCT02626130.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AztraZeneca.
Disclosure
M.T. Campbell: Honoraria (self): Pfizer; Honoraria (self): Genentech; Honoraria (self): Apricity Health LLC; Advisory / Consultancy: EMD Serono, Inc; Advisory / Consultancy: Genentech, Inc. E. Jonasch: Research grant / Funding (self), Research grant / Funding (institution): Exelixis; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Peloton; Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Eisai; Honoraria (self): Exelixis; Honoraria (self): Genentech; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche. A.Y. Shah: Honoraria (self): Eisai; Honoraria (self): Oncology Information Group; Honoraria (self): Roche Pharmaceuticals; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): BMS; Research grant / Funding (institution): EMD Serono. All other authors have declared no conflicts of interest.
Resources from the same session
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract